Twist Bioscience Co. (NASDAQ:TWST) COO Sells $278,259.40 in Stock

Twist Bioscience Co. (NASDAQ:TWST) COO Patrick John Finn sold 6,239 shares of the business’s stock in a transaction on Wednesday, November 6th. The shares were sold at an average price of $44.60, for a total transaction of $278,259.40. Following the sale, the chief operating officer now directly owns 231,401 shares in the company, valued at $10,320,484.60. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Patrick John Finn also recently made the following trade(s):

• On Monday, November 4th, Patrick John Finn sold 2,681 shares of Twist Bioscience stock. The stock was sold at an average price of $41.56, for a total value of $111,422.36.
• On Wednesday, October 23rd, Patrick John Finn sold 2,261 shares of Twist Bioscience stock. The shares were sold at an average price of $43.09, for a total value of $97,426.49.
• On Wednesday, October 2nd, Patrick John Finn sold 6,865 shares of Twist Bioscience stock. The stock was sold at an average price of $43.21, for a total value of $296,636.65.

Twist Bioscience Price Performance

Twist Bioscience stock opened at $45.40 on Monday. The stock has a market capitalization of $2.66 billion, a PE ratio of -11.88 and a beta of 1.78. The business has a 50 day simple moving average of $43.69 and a 200-day simple moving average of $45.74. Twist Bioscience Co. has a 12 month low of $15.85 and a 12 month high of $60.90.

Analyst Ratings Changes

Several brokerages recently issued reports on TWST. JPMorgan Chase & Co. raised their target price on shares of Twist Bioscience from $28.00 to $35.00 and gave the stock an “underweight” rating in a report on Monday, August 5th. Evercore ISI lifted their price objective on Twist Bioscience from $52.00 to $56.00 and gave the company an “outperform” rating in a research note on Tuesday, October 1st. Barclays lowered their target price on Twist Bioscience from $60.00 to $55.00 and set an “overweight” rating on the stock in a research note on Monday, August 5th. Leerink Partners lifted their price target on Twist Bioscience from $45.00 to $48.00 and gave the company a “market perform” rating in a research report on Thursday, October 17th. Finally, Robert W. Baird upped their price objective on Twist Bioscience from $40.00 to $46.00 and gave the stock an “outperform” rating in a research report on Monday, August 5th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and seven have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $51.22.

Hedge Funds Weigh In On Twist Bioscience

A number of large investors have recently added to or reduced their stakes in the stock. Signaturefd LLC grew its position in shares of Twist Bioscience by 63.0% in the third quarter. Signaturefd LLC now owns 792 shares of the company’s stock valued at $36,000 after purchasing an additional 306 shares during the period. EdgeRock Capital LLC purchased a new stake in Twist Bioscience during the 2nd quarter worth approximately $43,000. Blue Trust Inc. increased its stake in Twist Bioscience by 2,912.8% during the 2nd quarter. Blue Trust Inc. now owns 1,175 shares of the company’s stock worth $58,000 after buying an additional 1,136 shares in the last quarter. DekaBank Deutsche Girozentrale acquired a new position in shares of Twist Bioscience during the second quarter valued at approximately $61,000. Finally, Mirae Asset Global Investments Co. Ltd. lifted its position in shares of Twist Bioscience by 21.9% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,119 shares of the company’s stock valued at $98,000 after acquiring an additional 381 shares in the last quarter.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.